moksha8 Sees Profit

Last week's series D financing and deal with Watson Pharmaceuticals Inc. (NYSE:WPI), has given specialty pharma moksha8 Pharmaceuticals Inc. its first branded generic products and enough cash to get it to profitability, CEO Simba Gill told Ebb & Flow.

Founded in 2007, moksha8 focuses on partnering to sell branded drugs, novel therapeutics approved elsewhere, and now branded generics into Latin American markets, particularly Brazil and Mexico. Most of its products are for an increasingly affluent middle class with the means to pay out of pocket for recognizable brands and newer drugs...